SAMJIN PHARMACEUTICAL CO.,LTD Logo

SAMJIN PHARMACEUTICAL CO.,LTD

Researches & develops drugs for cardiovascular, respiratory, and gastrointestinal disorders.

005500 | KO

Overview

Corporate Details

ISIN(s):
KR7005500004
LEI:
Country:
South Korea
Address:
서울특별시 마포구 와우산로 121 삼진제약사옥, 마포구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Samjin Pharmaceutical Co., Ltd. is a Korean pharmaceutical company dedicated to the research, development, and manufacturing of treatments to improve human health. The company focuses on creating innovative therapies for diseases with high unmet medical needs, including cardiovascular, respiratory, and gastrointestinal disorders, with an ambition to become a global leader in the field. Through significant investment in R&D, Samjin has developed a diverse portfolio of both prescription and over-the-counter medications. Key products include the antiplatelet drug Plariss, the analgesic Geborin, and the hypercholesterolemia treatment Newstatin R. The company emphasizes securing technological competitiveness and building a robust pipeline of novel drugs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 126.6 KB
2025-08-27 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-08-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 126.6 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-07-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 96.6 KB
2025-07-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 96.6 KB
2025-07-07 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-05-12 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 27.9 KB
2025-05-12 00:00
Regulatory News Service
신탁계약해지결과보고서
Korean 18.4 KB
2025-03-21 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 25.7 KB
2025-03-21 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.2 KB
2025-03-21 00:00
Board/Management Information
대표이사(대표집행임원)변경(안내공시)
Korean 5.7 KB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 11.3 KB
2025-03-13 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.4 MB

Automate Your Workflow. Get a real-time feed of all SAMJIN PHARMACEUTICAL CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SAMJIN PHARMACEUTICAL CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SAMJIN PHARMACEUTICAL CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.